Heidelberg Pharma AG (F:HPHA) — Market Cap & Net Worth
Market Cap & Net Worth: Heidelberg Pharma AG (HPHA)
Heidelberg Pharma AG (F:HPHA) has a market capitalization of $139.89 Million (€119.65 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #17890 globally and #1674 in its home market, demonstrating a 1.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Heidelberg Pharma AG's stock price €2.78 by its total outstanding shares 46784317 (46.78 Million). Analyse how efficiently does Heidelberg Pharma AG generate cash to see how efficiently the company converts income to cash.
Heidelberg Pharma AG Market Cap History: 2015 to 2026
Heidelberg Pharma AG's market capitalization history from 2015 to 2026. Data shows growth from $88.88 Million to $152.05 Million (3.31% CAGR).
Heidelberg Pharma AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Heidelberg Pharma AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.53x
Heidelberg Pharma AG's market cap is 18.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $125.85 Million | $1.36 Million | -$6.39 Million | 92.40x | N/A |
| 2017 | $175.79 Million | $1.90 Million | -$10.97 Million | 92.52x | N/A |
| 2018 | $132.36 Million | $3.67 Million | -$11.67 Million | 36.09x | N/A |
| 2019 | $117.05 Million | $7.31 Million | -$10.15 Million | 16.01x | N/A |
| 2020 | $381.78 Million | $8.49 Million | -$18.37 Million | 44.98x | N/A |
| 2021 | $257.62 Million | $1.75 Million | -$26.14 Million | 147.22x | N/A |
| 2022 | $265.27 Million | $18.51 Million | -$19.70 Million | 14.33x | N/A |
| 2023 | $199.64 Million | $9.86 Million | -$20.35 Million | 20.25x | N/A |
| 2024 | $126.89 Million | $6.85 Million | -$19.38 Million | 18.53x | N/A |
Competitor Companies of HPHA by Market Capitalization
Companies near Heidelberg Pharma AG in the global market cap rankings as of May 3, 2026.
Key companies related to Heidelberg Pharma AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Heidelberg Pharma AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Heidelberg Pharma AG's market cap moved from $88.88 Million to $ 152.05 Million, with a yearly change of 3.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €152.05 Million | +15.83% |
| 2025 | €131.27 Million | +3.45% |
| 2024 | €126.89 Million | -36.44% |
| 2023 | €199.64 Million | -24.74% |
| 2022 | €265.27 Million | +2.97% |
| 2021 | €257.62 Million | -32.52% |
| 2020 | €381.78 Million | +226.17% |
| 2019 | €117.05 Million | -11.57% |
| 2018 | €132.36 Million | -24.70% |
| 2017 | €175.79 Million | +39.68% |
| 2016 | €125.85 Million | +41.60% |
| 2015 | €88.88 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Heidelberg Pharma AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $139.89 Million USD |
| MoneyControl | $139.89 Million USD |
| MarketWatch | $139.89 Million USD |
| marketcap.company | $139.89 Million USD |
| Reuters | $139.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more